Epignostix

Developer of DNA methylation-based therapeutics for tumor classification

placeHeidelberg, Baden-wurttemberg, Germany calendar_todayFounded 2022 language epignostix.com

Social engagement

Social engagement: 1.5K social following, 3 posts in the last 12 months — below the industry typical range.

Investor mix

9 investors on record.

Investor typeCountShare
Venture capital444%
Accelerator & incubator111%
Other / undisclosed444%

Recent activity

16 Jun 2026
Event
AMPEurope2026 Association for Molecular Pathology (AMP)
1 Jun 2026
Leadership hire
Chief Medical Advisor
Coming soon